 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
Merck Serono, Compugen Form Joint Venture to Develop Genomic Tests for Drug-Induced Toxicity
July 03, 2012
Merck Serono, Compugen Form Joint Venture to Develop Genomic Tests for Drug-Induced Toxicity
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Merck Serono, Compugen Form Biomarker Discovery Firm
June 25, 2012 / GenomeWeb Daily News - Merck KGaA, MDxHealth Explore Personalized Rx Strategy for Glioblastoma Patients with Methylated MGMT
July 11, 2012 / Pharmacogenomics Reporter - Merck Serono Survey Finds Limited Test Access, High Costs a Barrier to Personalized Rx Adoption in UK
May 2, 2012 / Pharmacogenomics Reporter - ASCO Reviewer Advises Genotyping to Improve Success for MEK-Inhibiting Cancer Drugs
June 9, 2010 / Pharmacogenomics Reporter - Study Experimentally Validates Compugen's Computationally Predicted Drug Target for Multiple Myeloma
May 14, 2010 / ProteoMonitor